Skip to main content
Article thumbnail
Location of Repository

Modes of Organizing Biomedical Innovation in the UK and US and the Role of Integrative and Relational Capabilities

By Jacky Swan, Anna Goussevskaia, Sue Newell, Maxine Robertson, Mike Bresnen and Ademola Obembe


This is the Authors' Final Draft of the version published as Research Policy, 36 (4, pp.529-547. This can be accessed online at

Publisher: Elsevier
Year: 2007
OAI identifier:

Suggested articles


  1. (1995). 4th Edition. Diffusion of Innovations.
  2. (2002). A comparison of US and European university-industry relations in the life sciences. doi
  3. (2002). A pragmatic view of knowledge and boundaries: boundary objects in new product development. doi
  4. (1990). Absorptive capacity: a new perspective on learning and innovation. doi
  5. (1994). American universities and technical advance in industry. doi
  6. (2000). An analysis of the critical role of public science in innovation: the case of biotechnology, doi
  7. (2003). Analyzing distributed processes of provision and innovation.
  8. (1987). Anglo-American Innovation. De Gruyter, doi
  9. (2005). Biotech-pharmaceutical alliances as a signal of asset and firm quality. doi
  10. (1981). Boundary spanning individuals: Their role in information transfer and their antecedents. doi
  11. (2005). Careers in public sector science: orientations and implications. doi
  12. (1995). Case studies, in:
  13. (2003). Competition and pluralism in the public sciences: the impact of institutional frameworks on the organisation of academic science. doi
  14. (2004). Coordination networks within and across organizations: a multi-level framework. doi
  15. (2005). Democritizing Innovation.
  16. (2005). Exchange under conflicting institutional logics: commerce and science in the world of population genetics.
  17. (2006). forthcoming. The incompatibility of knowledge regimes: consequences of the material world for cross-domain work. doi
  18. (2001). From Global to Metanational: How Companies Win in the Knowledge Economy. doi
  19. (2003). From separate systems to a hybrid order: accumulative advantage across public and private science at Research One universities. doi
  20. (1998). How venture capital works.
  21. (2003). Human tissue-engineered products: Today’s markets and future prospects. Report published by the Institute for Prospective Technological Studies.
  22. (2005). Indirect networks: an intangible resource for biotechnology innovation. doi
  23. (1993). Informal collaboration in R&D: the formation of networks across organizations. doi
  24. (2005). Innovation and Institutions: A Multidisciplinary Review of the Study of Innovation Systems. New Horizons of the Economics of Innovation series. doi
  25. (2005). Innovation and network structural dynamics: study of the alliance network of a major sector of the biotechnology industry. doi
  26. (2002). Innovation as co-evolution of scientific and technological networks: exploring tissue engineering. doi
  27. (2004). Innovation technology: exploring the impact of simulations on the innovation process. Paper presented at DRUID summer conference. Industrial Dynamics, Innovation and Development,
  28. (2005). Inside the FDA: The Business and Politics Behind the Drugs that We Take and the Food that We Eat. doi
  29. (2000). Institutional adaptiveness, technology policy, and the diffusion of new business models: the case of German biotechnology. doi
  30. (1998). Intellectual capital and the birth of US biotechnology enterprises. doi
  31. (1995). Interdependence and group effectiveness', doi
  32. (1996). Interorganizational collaboration and the locus of innovation: Networks of learning in biotechnology. doi
  33. (2002). Knowing in practice: enacting a collective capability in distributed organizing. doi
  34. (2004). Knowledge Networks as Channels and Conduits: The Effects of Spillovers in the Boston Biotechnology Community. doi
  35. (1990). Longitudinal field research on change: theory and practice. doi
  36. (2006). Match your innovation strategy to your innovation ecosystem.
  37. (1993). National Innovation Systems: A Comparative Analysis. doi
  38. (2001). National institutional frameworks and the hybridization of entrepreneurial business models: The German and UK biotechnology sectors. doi
  39. (1995). Occupational roles and expectations of research scientists and research managers in scientific research institutions. doi
  40. (2003). Organizational Innovations. doi
  41. (2000). Organizations Evolving. doi
  42. (1967). Organizations in Action, doi
  43. (2000). Organizations in Action: Competition Between Contexts. doi
  44. (1993). Organizations Working Together. doi
  45. (1997). Pasteurs Quadrant: Basic Science and Technological Innovation. doi
  46. (2005). Pharmaceutical industry project. Working Paper Series,
  47. (1994). Qualitative Data Analysis, doi
  48. (2001). Re-Thinking Science: Knowledge and the Public in an Age of Uncertainty. Polity, doi
  49. (2000). Reflexive Methodology: New Vistas for Qualitative Research. doi
  50. (2000). Research methods for business students. doi
  51. (2002). Resistance to innovation among US drug abuse treatment providers: When organizational knowledge interferes with organizational learning.
  52. (2003). Resources, knowledge and influence: the organizational effects of interorganizational collaboration. doi
  53. (1996). Social networks, learning and flexibility: souring scientific knowledge in new biotechnology firms. doi
  54. (1986). Some elements in a sociology of translation: domestication of the scallops and fisherman of St. Brieuc Bay. In doi
  55. (1998). Strategies of engagement: lessons from the critical examination of collaboration and conflict in an interorganizational domain. doi
  56. (2002). Technological Systems in the Bio Industries: An International Study. doi
  57. (2005). The creation of spin-off firms at public research institutions: managerial and policy implications. doi
  58. (2005). The diffusion of medical innovations: can configurational sociology contribute? doi
  59. (2003). The effects of upper echelon affiliations on underwriter prestige. doi
  60. (1994). The evolution of integrative capability: innovation in cardiovascular drug discovery. doi
  61. (1997). The impact of firm-specific capabilities on the amount of capital raised in an initial public offering: Evidence from the biotechnology industry. doi
  62. (2000). The Innovator’s Dilemma. doi
  63. (2000). The institutional structuring of innovation strategies: business systems, firm types and patterns of technical change in different market economies. doi
  64. (2003). The key to successful collaborations: rigorous and independent due diligence. doi
  65. (1994). The New Production of Knowledge: The Dynamics of Science and Research in Contemporary Societies. doi
  66. (1989). The validity of idiographic research explanations. doi
  67. (1978). Theoretical sensitivity: Advances in the methodology of grounded theory.
  68. (2004). Transferring, translating, and transforming: an integrative framework for managing knowledge across boundaries. doi
  69. (2006). Users’ contribution to radical innovation: evidence from four cases in the field of medical equipment technology. doi
  70. (2001). Varieties of Capitalism: The Institutional Foundations of Comparative Advantage. doi

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.